We are seeking a full-time Postdoctoral Researcher in Radiopharmaceutical Formulation and Delivery to join the Department of Oncology, Churchill Hospital, Oxford.You will be joining an established team working on an Engineering and Physical Research Council (EPSRC) funded project, investigating the use of ultrasound to enhance the delivery of drugs and genes. You will be appointed within the Department of Oncology and will interface very closely with other scientists appointed to this EPSRC programme, based in the Departments of Oncology, Engineering (Institute of Biomedical Engineering, IBME) and Clinical Medicine.You will hold (or be working towards) a PhD in biotechnology, biophysics, cell biology or pharmaceutical sciences with a strong interest in cancer biology, radiobiology and therapeutics. Experience of working with radiopharmaceuticals and formulation of drug delivery systems is also an essential requirement of the role. In addition, you will need to have (or obtain) a Home Office personal licence and will have experience of undertaking experiments in mouse models including tumour growth, treatment and survival studies. Familiarity with the principle of pharmacokinetics and drug delivery will be advantageous, as will familiarity with cancer biology and vascular structure.This is a full-time post and is offered for 1 year in the first instance with the possibility to extend to 2 years.All applicants must complete a short application form and upload a CV and supporting statement.The closing date for applications is 12.00 noon on 17 March 2017.
Postdoctoral Researcher in Radiopharmaceutical Formulation and Delivery
Friday, March 17, 2017 - 12:00
CRUK/MRC Oxford Institute for Radiation and Oncology
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.